多药耐药鲍氏不动杆菌生物膜形成能力的研究

Biofilm-forming ability of multidrug-resistant Acinetobacter baumannii

目的研究几种药物对临床分离的鲍氏不动杆菌最低抑菌浓度(MIC)及其生物被膜形成能力,为临床资料提供参考依据。方法 2012年4月-2012年6月收集医院临床分离的多药耐药鲍氏不动杆菌30株,用琼脂倍比稀释法定量分析多药耐药鲍氏不动杆菌生物被膜形成能力。结果 30株鲍氏不动杆菌临床分离株对头孢他啶、哌拉西林、阿米卡星的耐药株数为29株,耐药率均为96.6%,对头孢哌酮/舒巴坦、美罗培南的耐药株数为26株,耐药率均为86.7%,对哌拉西林/舒巴坦的耐药株数为28株,耐药率为93.9%;对左氧氟沙星的耐药株数为19株,耐药率为63.6%;30株鲍氏不动杆菌临床分离株均具有生物被膜形成能力且形成试验均为强阳性。结论该30株鲍氏不动杆菌均为多药耐药菌,且均具有较强的生物膜形成能力。

OBJECTIVE To study several kinds of drugs minimum inhibitory concentration （MICs） on A. baumannii isolated in the clinic and its biofilm-forming ability so as to provide reference for clinical data. METHODS 30 multi- drug resistant A. baumannii clinical isolates were collected 1 from Apr 2012 to Jun 2012. The biofilm-forming ability was analyzed quantitatively by agar dilution method. RESULTS Among the 30 multidrug resistant A. bau- mannii clinical isolates, 29 isolates were resistant to ceftazidime, piperacillin and amikacin with resistant rate of 96.6%; 26 isolates were resistant to cefoperzone/sulbactam and meropenem with resistant rate of 86. 7%; 28 isolates were resistant to piperacillin/sulbactam with resistant rate of 93.9%; 19 isolates were resistant to levo- floxacin with resistant rate of 63. 6%. All of isolates were strongly positive for biofilm-forming ability. CONCLUSION All of the 30 A. baumannii clinical isolates are multi-drug resistant, and all have strong ability to form biofilms.